GREENLAND MINES LTD (GRML)
NASDAQHealth CareOther Precious MetalsSnapshot 2026-09-04
$4.76+6.25%
Close 2026-09-04 · 1-day change
NASDAQHealth CareOther Precious MetalsSnapshot 2026-09-04
Research Workspace
Put GRML beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
No standing thesis yet — not enough to read.
View ThesisThis stock is highly volatile — it swings about 4% on a typical day and fell roughly 86% in its worst 12-month stretch.
View RiskGreenland Mines needs to advance its projects to justify its current price. The company expects to complete a $35 million acquisition soon. This acquisition will help fund development activities for the Sarfartoq project. Revenue growth is uncertain, and recent performance has been weak. The stock trades at a high multiple compared to peers. This suggests the market expects strong future growth. If the acquisition faces delays, it could hurt the thesis. Peer multiples imply a price about 48% below where it trades. This read is provisional.
Trailing returns as of 2026-09-04. GRML is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 1 analyst currently covering GRML (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare GRML with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| GRML Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Diversified Metals & Mining — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put GRML next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance multi-asset platform in rare earths and biotech sectors
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Advances multi-asset platform in rare earths and biotech sectors.
Advances: Pursue M&A to expand resource and technology base
Acquisition aligns with M&A growth strategy.
Advances: Pursue M&A to expand resource and technology base
Acquisition aligns with M&A growth strategy.
Advances: Pursue M&A to expand resource and technology base
Proposed offering directly supports M&A objective for growth.
Stock tumble indicates market concerns about funding strategy.
Advances: Pursue M&A to expand resource and technology base
Public offering supports M&A strategy for growth.
Advances: Advance multi-asset platform in rare earths and biotech sectors
Valuation supports growth in rare earths sector.
Advances: Advance multi-asset platform in rare earths and biotech sectors
Reverse stock split supports multi-asset platform advancement.
